Genetic influences on lipid metabolism trait variability within the Stanislas Cohort.

The contribution of 17 polymorphisms within 13 candidate genes on lipid trait variability was investigated by a multiplex assay in 772 men and 780 women coming for a health checkup examination. The studied genes were APOE, APOB, APOC3, CETP, LPL, PON, MTHFR, FGB, GpIIIa, SELE, ACE, and AGT. We found that APOB-Thr71Ile, APOE-(112/158), APOC3-1100C/T, and SELE-98G/T polymorphisms had a significant effect on lipid traits (P < or = 0.001 to P < or = 0.01). Genetic effects accounted for 3.5-5.7% of variation in apolipoprotein B (apoB)-related traits among men, and for 5.7-9.0% among women. The contribution of APOE polymorphism on apoB-related traits variability was two to three times more important in women than in men. We found suggestive evidence for interactive effects between genetics and age, smoking status, and oral contraceptives. Increase of LDL-cholesterol and apoB concentrations with age was stronger among the epsilon4 carriers in women, and apolipoprotein A-I (apoA-I) concentration decreased with age in epsilon4 male carriers. The effect of epsilon2 allele on LDL-cholesterol was more important in the oral contraceptive users. In nonsmokers only, the APOC3-1100C allele in women was related to lower apoB-related traits concentrations, and in men to higher apoA-I and HDL-cholesterol concentrations. In conclusion, this work, in addition to the reinforcement of the already known associations between APOB, APOE, and APOC3 genes and lipids, leads to new perspectives in the complex relationships among genes and environmental factors. The newly observed relationships between E-selectine gene and lipid concentrations support the hypotheses of multiple metabolic pathways contributing to the complexity of lipids variability.

[1]  C. Ballantyne,et al.  Levels of Soluble Cell Adhesion Molecules in Patients With Dyslipidemia , 1996 .

[2]  W. Castelli,et al.  Epidemiology of coronary heart disease: the Framingham study. , 1984, The American journal of medicine.

[3]  B. Nordestgaard,et al.  Lipoprotein Lipase Mutations, Plasma Lipids and Lipoproteins, and Risk of Ischemic Heart Disease A Meta-Analysis , 1999 .

[4]  O H Førde,et al.  The Tromsø Study. Distribution and population determinants of gamma-glutamyltransferase. , 1990, American journal of epidemiology.

[5]  M J Malloy,et al.  A multilocus genotyping assay for candidate markers of cardiovascular disease risk. , 1999, Genome research.

[6]  P. Barter.  INHIBITION OF ENDOTHELIAL CELL ADHESION MOLECULE EXPRESSION BY HIGH DENSITY LIPOPROTEINS , 1997, Clinical and experimental pharmacology & physiology.

[7]  P. Wilson,et al.  Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. , 1980, The American journal of cardiology.

[8]  D. Wilcken,et al.  Relationship between total plasma homocysteine, polymorphisms of homocysteine metabolism related enzymes, risk factors and coronary artery disease in the Australian hospital-based population. , 1999, Atherosclerosis.

[9]  M. Rosseneu,et al.  Physological significance of apolipoprotein mutants , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  L. Hayman.  Abnormal blood lipids: is it environment or is it genes? , 2000, The Journal of cardiovascular nursing.

[11]  R. Krauss,et al.  Candidate-gene studies of the atherogenic lipoprotein phenotype: a sib-pair linkage analysis of DZ women twins. , 1998, American journal of human genetics.

[12]  Y. Ueki,et al.  High serum concentrations of soluble E-selectin in patients with impaired glucose tolerance with hyperinsulinemia. , 2000, Atherosclerosis.

[13]  A. Hedley,et al.  The relationship between fibrinogen and other coronary heart disease risk factors in a Chinese population. , 1999, Atherosclerosis.

[14]  S. Humphries,et al.  Associations of genotypes at the apolipoprotein AI‐CIII‐AIV, apolipoprotein B and lipoprotein lipase gene loci with coronary atherosclerosis and high density lipoprotein subclasses , 1994, Clinical genetics.

[15]  C. Bunker,et al.  Genetic association of five apolipoprotein polymorphisms with serum lipoprotein‐lipid levels in African blacks , 1999, Genetic epidemiology.

[16]  A. Gnasso,et al.  Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine and other risk factors for vascular disease. , 1998, Atherosclerosis.

[17]  J. Viikari,et al.  DNA polymorphisms of the apolipoprotein B and A-I/C-III genes are associated with variations of serum low density lipoprotein cholesterol level in childhood. , 1991, Journal of lipid research.

[18]  T. Dantoine,et al.  Paraoxonase as a Risk Marker for Cardiovascular Disease: Facts and Hypotheses , 1998, Clinical chemistry and laboratory medicine.

[19]  A. Kessling,et al.  Patterns of association between genetic variability in apolipoprotein (apo) B, apo AI-CIII-AIV, and cholesterol ester transfer protein gene regions and quantitative variation in lipid and lipoprotein traits: influence of gender and exogenous hormones. , 1992, American journal of human genetics.

[20]  R. Coleman,et al.  Angiotensin II atherogenicity in apolipoprotein E deficient mice is associated with increased cellular cholesterol biosynthesis. , 1999, Atherosclerosis.

[21]  M. Sentí,et al.  The relationship between smoking and triglyceride-rich lipoproteins is modulated by genetic variation in the glycoprotein IIIa gene. , 1998, Metabolism: clinical and experimental.

[22]  G. Schellenberg,et al.  Evidence that the apolipoprotein E-genotype effects on lipid levels can change with age in males: a longitudinal analysis. , 1997, American journal of human genetics.

[23]  V. Gudnason,et al.  C677T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): its frequency and impact on plasma homocysteine concentration in different European populations. EARS group. , 1997, Atherosclerosis.

[24]  P. Wilson,et al.  Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma lipoprotein levels. Results from the Framingham Offspring Study. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[25]  C. Sing,et al.  The gender-specific apolipoprotein E genotype influence on the distribution of plasma lipids and apolipoproteins in the population of Rochester, MN. III. Correlations and covariances. , 1994, American journal of human genetics.

[26]  M J Malloy,et al.  A Multilocus Genotyping Assay for Cardiovascular Disease , 1998, Clinical chemistry and laboratory medicine.

[27]  P. Grant,et al.  Soluble vascular cell adhesion molecule-1 and E-selectin levels in relation to vascular risk factors and to E-selectin genotype in the first degree relatives of NIDDM patients and in NIDDM patients , 1998, Diabetologia.

[28]  E. Pamies-Andreu,et al.  [The effect of the angiotensinogen M235T and the angiotensin-converting enzyme I/D polymorphisms on arterial hypertension and other cardiovascular risk factors]. , 1999 .

[29]  C. Sing,et al.  The gender-specific apolipoprotein E genotype influence on the distribution of plasma lipids and apolipoproteins in the population of Rochester, Minnesota. II. Regression relationships with concomitants. , 1992, American journal of human genetics.

[30]  Chun-Fang Xu,et al.  Association between genetic variation at the APO AI‐CIII‐AIV gene cluster and familial combined hyperlipidaemia , 1994, Clinical genetics.

[31]  J. Strong,et al.  Lipid and apolipoprotein predictors of atherosclerosis in youth: apolipoprotein concentrations do not materially improve prediction of arterial lesions in PDAY subjects. The PDAY Research Group. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[32]  S. Eisenberg,et al.  Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. , 1991, The Journal of biological chemistry.

[33]  M. Aviram,et al.  Angiotensin II-modified LDL is taken up by macrophages via the scavenger receptor, leading to cellular cholesterol accumulation. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[34]  R. Hamman,et al.  The relationship of APOE polymorphism and cholesterol levels in normoglycemic and diabetic subjects in a biethnic population from the San Luis Valley, Colorado. , 1995, Atherosclerosis.

[35]  V. Gudnason,et al.  Variation at the lipoprotein lipase and apolipoprotein AI‐CIII gene loci are associated with fasting lipid and lipoprotein traits in a population sample from Iceland: Interaction between genotype, gender, and smoking status , 1997, Genetic epidemiology.

[36]  Wen-Hsiung Li,et al.  Structure of Apolipoprotein B‐100 of Human Low Density Lipoproteins , 1989, Arteriosclerosis.

[37]  V. Gudnason,et al.  Interaction of the cholesteryl ester transfer protein I405V polymorphism with alcohol consumption in smoking and non‐smoking healthy men, and the effect on plasma HDL cholesterol and apoAI concentration , 1997, Clinical genetics.

[38]  P. Savage,et al.  Association of Fibrinogen and Coagulation Factors Vll and VIII with Cardiovascular Risk Factors in the Elderly The Cardiovascular Health Study , 1996 .

[39]  A. Tall.  Plasma cholesteryl ester transfer protein. , 1993, Journal of lipid research.

[40]  G Siest,et al.  Objectives, Design and Recruitment of a Familial and Longitudinal Cohort for Studying Gene-Environment Interactions in the Field of Cardiovascular Risk: The Stanislas Cohort , 1998, Clinical chemistry and laboratory medicine.

[41]  P. Talmud,et al.  European Atherosclerosis Research Study: genotype at the fibrinogen locus (G-455-A beta-gene) is associated with differences in plasma fibrinogen levels in young men and women from different regions in Europe. Evidence for gender-genotype-environment interaction. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[42]  J. Viikari,et al.  Apolipoprotein B polymorphism and altered apolipoprotein B and low density lipoprotein cholesterol concentrations in Finnish children , 1988, British medical journal.

[43]  J. Ordovás,et al.  Genes, variation of cholesterol and fat intake and serum lipids. , 1999, Current opinion in lipidology.

[44]  C. Sing,et al.  Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. , 1985, American journal of human genetics.

[45]  P. de Knijff,et al.  Genetic analysis of sex and generation differences in plasma lipid, lipoprotein, and apolipoprotein levels in adolescent twins and their parents , 1996, Genetic epidemiology.

[46]  L. Taylor,et al.  Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine metabolism and late-onset vascular disease. , 1996, Circulation.

[47]  E. Boerwinkle,et al.  Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[48]  Guy Hoffman,et al.  Estradiol enhances leukocyte binding to tumor necrosis factor (TNF)-stimulated endothelial cells via an increase in TNF-induced adhesion molecules E-selectin, intercellular adhesion molecule type 1, and vascular cell adhesion molecule type 1. , 1994, The Journal of clinical investigation.

[49]  W. Kannel,et al.  Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. , 1979, Annals of internal medicine.

[50]  B. Binder,et al.  Purification and identification of the lipoprotein-binding proteins from human blood platelet membrane. , 1989, The Journal of biological chemistry.

[51]  B. Zinman,et al.  Common genomic variants associated with variation in plasma lipoproteins in young aboriginal Canadians. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[52]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[53]  B. Zinman,et al.  Common genomic variation in the APOC3 promoter associated with variation in plasma lipoproteins. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[54]  C. Sing,et al.  Sources of variation in plasma lipid and lipoprotein traits in a sample selected for health. , 1999, American journal of epidemiology.

[55]  K. Bønaa,et al.  Association Between Blood Pressure and Serum Lipids in a Population: The Tromsø Study , 1991, Circulation.

[56]  H. Lindmark,et al.  Oxysterols present in atherosclerotic tissue decrease the expression of lipoprotein lipase messenger RNA in human monocyte-derived macrophages. , 1996, The Journal of clinical investigation.

[57]  S C Hunt,et al.  Genetic basis of familial dyslipidemia and hypertension: 15-year results from Utah. , 1993, American journal of hypertension.

[58]  R. Norum,et al.  Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. , 1986, The Journal of clinical investigation.

[59]  J. Saklatvala,et al.  High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[60]  R. Hegele,et al.  Multiple genetic determinants of variation of plasma lipoproteins in Alberta Hutterites. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[61]  P. Marraccini,et al.  Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia. , 1997, Circulation.